Genentech’s Vabysmo Slowly Chips Away at Competition in the Neovascular (Wet) AMD Market While Regeneron’s Eylea Holds its Ground (For Now), According to New Spherix Report

Newer ranibizumab entrants, Byooviz (Samsung/Biogen) and Susvimo (Genentech), struggle to make an impact EXTON, Pa., Sept. 1, 2022 /PRNewswire/ -- Since the FDA approval in January this year, ophthalmologists have been very optimistic about their intended use of Genentech's Vabysmo...

Click to view original post